BUY Aurobindo Pharma — Raja Venkatraman, 05 Nov 2026

BUYAurobindo Pharma

Aurobindo Pharma share price target & all analyst calls

byRaja VenkatramanHorizon: 1–3 months5 Nov 2026via LiveMint Buy-or-Sell (topic)

Entry₹1,720Stated

Target₹1,875

Total upside +9.01%

Stop loss₹1,620-5.81% risk

CMP₹1,8001d ago

Active+4.65%+4.17%upside left 3 mo left

Follow Raja Venkatraman for new calls(24% target hit, 68 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 73 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:25 pm IST

6 supporting3 neutral1 opposing

Supports the BUY call (6)

MACD above its signal line — bullish momentum

Technicals · macd·7 Nov · today

5 advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days

Advisor consensus · adjacent horizon·6 Nov · yesterday

Aurobindo Pharma Q2 profit rises 33%, beats estimates; declares ₹7 interim dividend

NewsCnbc-Tv18·4 Nov · 2d ago

Aurobindo Pharma Q2 Results: Profit Rises 33%, Shareholders To Get Dividend By Nov 20

NewsNdtv-Profit·4 Nov · 2d ago

Aurobindo Pharma reported Q2 FY27 consolidated revenue of INR 10,263 Cr (up 24% YoY) and net profit of INR 1,124 Cr (up 32.5% YoY). The company also declared an interim dividend of INR 7.0 per share.

NSE · Press Release·4 Nov · 2d ago

Neutral / worth noting (3)

The company transferred ownership of its Russian subsidiary, Auro Pharma LLC, between two of its wholly owned subsidiaries.

BSE · Company Update·4 Nov · 2d ago

Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·4 Nov · 2d ago

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 3w ago

Weighs against the BUY call (1)

3 advisors have active long-term SELL calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·5 Nov · 2d ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Raja Venkatraman

Every call and its outcome